— Isabelle Laurence, Emilie Dubernay & Adam Hutchings
In recognition of Rare Disease Day 2025, we turn our attention to EU Joint Clinical Assessment (JCA), to explore the potential impact of JCA across three key dimensions important to sustaining investment and launch of new rare disease treatments in Europe.
